Seegnal Inc. Announces the Release of Its New "MetricsGuard" Clinical Decision Support Module

Executive Summary

• Seegnal Inc. announced completion of development and upcoming deployment of a new analytics module, “MetricsGuard,” enhancing its SaaS clinical decision‑support platform.
• MetricsGuard adds patient‑specific risk detection (contraindicated or severe warnings) beyond existing drug‑drug interaction alerts, targeting conditions such as hypoglycemia with sulfonylureas, hyponatremia with diuretics, etc.
• The module is slated for release in Q4 2025, with the first two customer orders already signed; Seegnal expects it to improve patient safety, reduce emergency visits and clinician burnout, and generate cost savings for healthcare organizations.

Key Details

• Module Name & Function: “MetricsGuard” – an intelligent analytics layer that continuously analyzes real‑time patient data (lab results, vital signs, serum drug levels) to generate alerts for single‑drug‑to‑patient metric risks.
• Risk Scenarios Covered:
• Hypoglycemia + sulfonylureas
• Hyponatremia + diuretics
• Bradycardia + beta‑blockers
• Hypocalcemia + denosumab
• Predisposing factors (e.g., hypokalemia/hypomagnesemia + digoxin)
• Deployment Timeline: Anticipated release in Q4 2025; first two orders already secured.
• Clinical Impact Claims:
• Generates “Contraindicated” or “Severe” alerts to prompt clinician intervention.
• Expected to decrease emergency care visits, hospitalizations, and re‑visits.
• Projected to reduce clinician burnout and improve patient quality of life.
• Strategic Positioning: Enhances Seegnal’s patient‑centric standard, differentiating it from legacy competitors and expanding functionality beyond the existing drug‑to‑drug interaction framework.
• Market Reach: Current SaaS platform deployed in Israel (adopted as national standard), UAE, United Kingdom, United States, Poland; serves >10,000 clinicians daily.
• Executive Quote: “This module will further differentiate and distinguish Seegnal from its legacy competitors… directly save money to healthcare organizations by decreasing the number of Emergency Care, hospitalization and re‑visits, decrease clinicians burn‑out and improve patient quality of living.” – Eyal Schneid, CEO

Notable Quotes

• Eyal Schneid, CEO: “This module will further differentiate and distinguish Seegnal from its legacy competitors, providing unmatched, yet much‑needed clinical value. This module will directly save money to healthcare organizations by decreasing the number of Emergency Care, hospitalization and re‑visits, decrease clinicians burn‑out and improve patient quality of living.”